Company Overview - Ascentage is a public company dual listed on NASDAQ and Hong Kong Stock Exchange with close to 800 employees [2] - The company is in a commercial stage in China with 2 novel products for oncology indications in hematology and is experiencing rapid growth [2] Product Pipeline - Ascentage has a pipeline of 7 disclosed compounds, including the 2 products mentioned, each with novel, best-in-class potential targeting major markets in hematology [3] - The company possesses an internal discovery engine to support its product development [3] Global Strategy - The employee distribution is predominantly in China, focusing on discovery, innovation, clinical trial execution, and sales, while over 100 employees are based in the U.S. [4] - The U.S. is identified as the global market hub for Ascentage, with 4 ongoing U.S. registration studies, marking the next chapter in the company's global commercial expansion [4]
Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript